TWI918751B - 用於治療疾病之雙環化合物及其用途 - Google Patents

用於治療疾病之雙環化合物及其用途

Info

Publication number
TWI918751B
TWI918751B TW110140600A TW110140600A TWI918751B TW I918751 B TWI918751 B TW I918751B TW 110140600 A TW110140600 A TW 110140600A TW 110140600 A TW110140600 A TW 110140600A TW I918751 B TWI918751 B TW I918751B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
alkyl
Prior art date
Application number
TW110140600A
Other languages
English (en)
Chinese (zh)
Other versions
TW202233622A (zh
Inventor
蓮恩 卡娃斯
凱文 雀曲
羅伯特 泰勒
傑韋爾 強斯頓
道格拉斯 保特曼
Original Assignee
美商里歐納生物股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商里歐納生物股份有限公司 filed Critical 美商里歐納生物股份有限公司
Publication of TW202233622A publication Critical patent/TW202233622A/zh
Application granted granted Critical
Publication of TWI918751B publication Critical patent/TWI918751B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW110140600A 2020-11-02 2021-11-01 用於治療疾病之雙環化合物及其用途 TWI918751B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108660P 2020-11-02 2020-11-02
US63/108,660 2020-11-02

Publications (2)

Publication Number Publication Date
TW202233622A TW202233622A (zh) 2022-09-01
TWI918751B true TWI918751B (zh) 2026-03-21

Family

ID=81384389

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110140600A TWI918751B (zh) 2020-11-02 2021-11-01 用於治療疾病之雙環化合物及其用途

Country Status (13)

Country Link
US (1) US20240025903A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236944A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884275B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230104191A (cg-RX-API-DMAC7.html)
CN (2) CN116568301A (cg-RX-API-DMAC7.html)
AR (1) AR124637A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021371026A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196582A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001195A1 (cg-RX-API-DMAC7.html)
IL (1) IL302465A (cg-RX-API-DMAC7.html)
MX (1) MX2023004942A (cg-RX-API-DMAC7.html)
TW (1) TWI918751B (cg-RX-API-DMAC7.html)
WO (1) WO2022094400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases
KR20250005323A (ko) * 2022-05-04 2025-01-09 아티라 파마, 인코포레이티드 신경병증을 치료하는 방법
US20250275976A1 (en) * 2022-05-04 2025-09-04 Athira Pharma, Inc. Methods of Treating Neuroinflammatory Conditions
JP2025538382A (ja) 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035587A1 (en) 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
TW201825493A (zh) 2015-09-18 2018-07-16 國立大學法人鳥取大學 利用低分子化合物的癌及纖維化的抑制和再生促進的效果

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2006036981A2 (en) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity
US7879898B1 (en) * 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
US8691819B2 (en) * 2008-10-14 2014-04-08 Prism Biolab Corporation Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
US20160074400A1 (en) * 2012-08-06 2016-03-17 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035587A1 (en) 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
TW201825493A (zh) 2015-09-18 2018-07-16 國立大學法人鳥取大學 利用低分子化合物的癌及纖維化的抑制和再生促進的效果

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 Eguchi, Masakatsu, et al. "Solid-phase synthesis and solution structure of bicyclic β-turn peptidomimetics: diversity at the i position." Tetrahedron Letters 42.7 (2001): 1237-1239.
期刊 La Venia, Agustina, Barbora Lemrová, and Viktor Krchnak. "Regioselective Incorporation of Backbone Constraints Compatible with Traditional Solid-Phase Peptide Synthesis." ACS Combinatorial Science 15.1 (2013): 59-72.
網路文獻 STN CAS Registry Number: 949893-44-1、949893-45-2, Date Entered STN: 2007.10.10。

Also Published As

Publication number Publication date
EP4236944A1 (en) 2023-09-06
CL2024000340A1 (es) 2024-08-16
CN116568301A (zh) 2023-08-08
US20240025903A1 (en) 2024-01-25
CN119684295A (zh) 2025-03-25
CA3196582A1 (en) 2022-05-05
AU2021371026A1 (en) 2023-06-15
JP2023550543A (ja) 2023-12-01
AU2021371026A9 (en) 2024-04-18
JP7884275B2 (ja) 2026-07-03
KR20230104191A (ko) 2023-07-07
AR124637A1 (es) 2023-04-19
IL302465A (en) 2023-06-01
CL2023001195A1 (es) 2023-10-20
TW202233622A (zh) 2022-09-01
MX2023004942A (es) 2023-07-06
EP4236944A4 (en) 2024-09-04
WO2022094400A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
TW202233622A (zh) 用於治療疾病之雙環化合物及其用途
CN111494386A (zh) 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
KR20230175222A (ko) Nek7 억제제
TW202339756A (zh) 雙環化合物用於治療疾病之用途
TW202406554A (zh) 治療神經發炎性病況之方法
TW202408503A (zh) 治療纖維化之方法
HK40122844A (en) Bicyclic compounds and uses thereof for the treatment of diseases
HK40097563A (en) Bicyclic compounds and uses thereof for the treatment of diseases
HK40113746A (en) Uses of bicyclic compounds for the treatment of diseases
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
CN118382441A (zh) 双环化合物用于治疗疾病的用途
US20260109690A1 (en) Hdac6 inhibitors and method of their use
TW202402284A (zh) 治療神經病變之方法
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний
RU2860767C2 (ru) Ингибиторы nek7
TW202523670A (zh) Pde 7調節劑化合物